Research Articles

Explore upcoming scientific meetings and educational events focused on advancing collaboration, sharing new evidence, and strengthening best practices in the care of patients with cancer-related cardiovascular conditions.

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.

Authors:

Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ.

Publication:

Spingerplus

Date:

2014 May 12

Article Link

Cancer Treatment–Related Cardiotoxicity: Current State of Knowledge and Future Research Priorities

Authors:

Nonniekaye Shelburne, Bishow Adhikari, Joanna Brell, Myrtle Davis, Patrice Desvigne-Nickens, Andrew Freedman, Lori Minasian, Thomas Force, Scot C. Remick

Publication:

Journal of the National Institute of Cancer

Date:

September 10, 2014

Article Link

Cancer-drug discovery and cardiovascular surveillance.

Authors:

Groarke JD, Cheng S, Moslehi J.

Publication:

New England Journal of Medicine

Date:

2013 Nov 7

Article Link

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Authors:

Sean A. Virani, MD, MSc, MPH, FRCPC (Co-Chair, Primary Panel)∗,correspondencePress enter key for correspondence informationemailPress enter key to Email the author, Susan Dent, MD, FRCPC (Co-Chair, Primary Panel)∗, Christine Brezden-Masley, MD, PhD, FRCPC (Primary Panel), Brian Clarke, MD, FRCPC, FACC (Primary Panel), Margot K. Davis, MD, FRCPC (Primary Panel), Davinder S. Jassal, MD, FACC, FRCPC (Primary Panel), Christopher Johnson, MD, FRCPC (Primary Panel), Julie Lemieux, MD, MSc, FRCPC (Primary Panel), Ian Paterson, MD, FRCPC (Primary Panel), Igal A. Sebag, MD, FRCPC, FACC, FASE (Primary Panel), Christine Simmons, MD, MSc, FRCPC (Primary Panel), Jeffrey Sulpher, MD, FRCPC (Primary Panel), Kishore Thain, MD, FRCPC (Primary Panel), Paaldinesh Thavendiranathan, MD, MSc, FRCPC (Primary Panel), Jason R. Wentzell, BScPharm, ACPR (Primary Panel), Nola Wurtele, MN, NP(A) (Primary Panel), Marc André Côté, MD, FRCPC (Secondary Panel), Nowell M. Fine, MD, MS, FRCPC (Secondary Panel), Haissam Haddad, MD, FRCPC, FACC (Secondary Panel), Bradley D. Hayley, MD, FRCPC (Secondary Panel), Sean Hopkins, BSc (Hon), BSP (Secondary Panel), Anil A. Joy, MD (Secondary Panel), Daniel Rayson, MD, FRCPC, FACP (Secondary Panel), Ellamae Stadnick, MD, MSc, FRCPC (Secondary Panel), Lynn Straatman, MD, FRCPC (Secondary Panel)

Publication:

Canadian Journal of Cardiology

Date:

July 2016

Article Link

Anthracycline-related cardiotoxicity in childhood cancer survivors.

Authors:

Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL.

Publication:

Current Opinion in Cardiology

Date:

2014 Jan

Article Link

Breast Cancer Chemotherapy and Your Heart

Authors:

Christine Unitt, Kamaneh Montazeri, Sara Tolaney, Javid Moslehi

Publication:

Circulation

Date:

2014

Article Link

BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography.

Authors:

Skovgaard D, Hasbak P, Kjaer A.

Publication:

PLoS One

Date:

2014 May 6

Article Link

Amelioration of doxorubicin induced cardio-and hepato-toxicity by carotenoids.

Authors:

Indu R, Azhar TS, Nair A, Nair CK.

Publication:

Journal of Cancer Research and Therapeutics

Date:

2014 Jan-Mar

Article Link

An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity

Authors:

Bhave M, Shah AN, Akhter N, Rosen ST.

Publication:

Current Opinion in Oncology

Date:

2014 Sep 17

Article Link

Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.

Authors:

Raj S, Franco VI, Lipshultz SE.

Publication:

Current Treatment Options in Cardiovascular Medicine

Date:

2014 Jun

Article Link